Crizotinib is an anti-cancer medication approved by the FDA in January 2021 for non-small cell lung carcinoma (NSCLC) treatment through the inhibition of both anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) [34,35]. This evidence concerns the gene ALK and non-small cell lung carcinoma.